中国生物制药2024年度盈利增长约50.1% 创新产品收入达120.6亿元

格隆汇资讯
20 Mar

格隆汇3月20日丨中国生物制药(01177.HK)发布公告,截至2024年12月31日止年度,集团录得收入约人民币2,886,616万元,较去年同期增长约10.2%。毛利约人民币2,352,994万元,较去年同期增长约10.9%。中药现代制剂及西药业务分部的毛利约为人民币2,345,000万元,较去年同期增长约11.0%。其他业务分部的毛利合计约为人民币7,994万元,较去年同期减少约5.6%。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10